PMV Pharmaceuticals Inc
PMVP
Company Profile
Business description
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
Contact
400 Alexander Park Drive
Suite 301
PrincetonNJ08540
USAT: +1 609 642-6670
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
47
Stocks News & Analysis
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
stocks
Major ASX listed miners overvalued
We’ve adjusted our fair values after updating our commodity price assumptions.
stocks
Undervalued ASX share with pathway to positive cash flow
Higher sales and a new loan facility increase our conviction.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,192.60 | 14.70 | -0.16% |
| CAC 40 | 8,258.94 | 54.18 | -0.65% |
| DAX 40 | 25,297.13 | 55.26 | -0.22% |
| Dow JONES (US) | 49,359.33 | 83.11 | -0.17% |
| FTSE 100 | 10,235.29 | 3.65 | -0.04% |
| HKSE | 26,582.52 | 262.44 | -0.98% |
| NASDAQ | 23,515.39 | 14.63 | -0.06% |
| Nikkei 225 | 53,433.18 | 502.99 | -0.93% |
| NZX 50 Index | 13,580.29 | 137.81 | -1.00% |
| S&P 500 | 6,940.01 | 4.46 | -0.06% |
| S&P/ASX 200 | 8,872.90 | 10.80 | -0.12% |
| SSE Composite Index | 4,107.91 | 6.00 | 0.15% |